Promising Bimarker Prediction of Outcome of HELLP Syndrome.

Status Completed

Clinical Trial Summary

HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia. And may occasionally be confused with other diseases complicating pregnancy such as acute fatty liver of pregnancy, gastroenteritis, hepatitis, appendicitis, gallbladder disease, immune thrombocytopenia, lupus flare, antiphospholipid syndrome, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and nonalcoholic fatty liver disease. The distinction between thrombotic thrombocytopenic purpura-hemolytic uremic syndrome and severe preeclampsia is important for therapeutic and prognostic reasons. However, the clinical and histological features are so similar that establishing the correct diagnosis is often difficult; furthermore, these disorders may occur concurrently.

Clinical Trial Description

When TTP/HUS does occur during pregnancy, they often are confused initially with obstetric diagnoses such as severe preeclampsia; hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome; acute fatty liver of pregnancy; eclampsia, and antiphospholipid antibody syndrome. This might be related to the fact that the disease entity is rare and often is unexpected. Nevertheless, a delay in diagnosis of TTP/HUS may result in life-threatening maternal and fetal consequences. Aim of the current study was to compare the quantitative assessment of schistocytes in peripheral blood smear between women initially diagnosed as HELLP syndrome who showed no spontaneous resolution within 48 hrs after delivery and those who showed spontaneous resolution within 48 hrs after delivery which may help in decreasing the maternal mortality rate . ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03246542
Study type	Observational [Patient Registry]
Source	Ain Shams Maternity Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 1, 2015
Completion date	June 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Recruiting	`NCT02247297` - Pancreatic Stone Protein (PSP) in Pregnant Women
Terminated	`NCT04725812` - Complement Regulation to Undo Systemic Harm in Preeclampsia	Phase 2
Recruiting	`NCT02020174` - The Preeclampsia Registry
Recruiting	`NCT06377878` - The Preeclampsia Registry
Recruiting	`NCT02920593` - A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy	Phase 4
Recruiting	`NCT01138839` - Dexamethasone Efficacy in HELLP I Syndrome	Phase 3
Recruiting	`NCT05500989` - PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Completed	`NCT04216706` - Early Vascular Adjustments to Prevent Preeclampsia
Recruiting	`NCT03834285` - Liver Disease in Pregnancy
Completed	`NCT00000534` - Calcium for Pre-Eclampsia Prevention (CPEP)	Phase 3
Recruiting	`NCT02807324` - Women Specific Cardiac Recovery After Preeclampsia
Completed	`NCT01736826` - Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Terminated	`NCT00711841` - Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome	Phase 4
Completed	`NCT00097110` - RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil	Phase 3
Completed	`NCT03715647` - Correlation of Survival in Puerperae by Electrical Impedance Tomography
Completed	`NCT03455387` - Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Completed	`NCT03232359` - Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome	N/A
Not yet recruiting	`NCT06452498` - Preeclampsia Intervention Netherlands	Phase 3